Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis.

Autor: Jedlowski PM; Division of Dermatology, Banner University Medical Center, University of Arizona College of Medicine - Tucson, 1765 N Pima Canyon Dr, Tucson, AZ, 85718, USA. pjedlowski@email.arizona.edu., Anthony M; University of Arizona College of Medicine - Tucson, Tucson, USA.

Publikováno v: Lasers in medical science [Lasers Med Sci] 2023 Dec 13; Vol. 39 (1), pp. 4. Date of Electronic Publication: 2023 Dec 13.

Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study.

Autor: Jedlowski PM; Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona. Electronic address: pjedlowski@email.arizona.edu., Jedlowski MF; Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona., Fazel M; Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Aug; Vol. 89 (2), pp. 408-410. Date of Electronic Publication: 2023 Apr 15.

Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Autor: Jedlowski PM; 12216 Division of Dermatology, University of Arizona College of Medicine - Tucson, Tucson, AZ, USA.

Publikováno v: Journal of cutaneous medicine and surgery [J Cutan Med Surg] 2023 Jan-Feb; Vol. 27 (1), pp. 39-43. Date of Electronic Publication: 2022 Dec 10.

Topical ophthalmic beta-blockers are associated with ocular pseudopemphigoid: A pharmacovigilance study of antiglaucoma medications utilising the FDA adverse event reporting system.

Autor: Jedlowski PM; Division of Dermatology - Tucson, University of Arizona College of Medicine, Tucson, Arizona, USA., Jedlowski MF; Division of Dermatology - Tucson, University of Arizona College of Medicine, Tucson, Arizona, USA.

Publikováno v: The Australasian journal of dermatology [Australas J Dermatol] 2022 May; Vol. 63 (2), pp. 222-227. Date of Electronic Publication: 2022 Mar 22.

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.

Autor: Jedlowski PM; Division of Dermatology, University of Arizona College of Medicine - Tucson, 7165 N Pima Canyon Dr, Tucson, AZ, 85718, USA. pjedlowski@email.arizona.edu., Jedlowski MF; Division of Dermatology, University of Arizona College of Medicine - Tucson, 7165 N Pima Canyon Dr, Tucson, AZ, 85718, USA., Fazel MT; Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, AZ, USA.; Division of Endocrinology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Banner University Medicine Diabetes and Endocrinology Clinic, Tucson, AZ, USA.

Publikováno v: American journal of clinical dermatology [Am J Clin Dermatol] 2021 Nov; Vol. 22 (6), pp. 891-900. Date of Electronic Publication: 2021 Jul 21.